- Home
- REFI vs CCCC Comparison
REFI vs CCCC Comparison
Compare REFI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- CCCC
- Stock Information
- Founded
- REFI 2021
- CCCC 2015
- Country
- REFI United States
- CCCC United States
- Employees
- REFI N/A
- CCCC N/A
- Industry
- REFI Real Estate Investment Trusts
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- CCCC Health Care
- Exchange
- REFI Nasdaq
- CCCC Nasdaq
- Market Cap
- REFI 274.3M
- CCCC 175.1M
- IPO Year
- REFI 2021
- CCCC 2020
- Fundamental
- Price
- REFI $13.37
- CCCC $3.57
- Analyst Decision
- REFI Strong Buy
- CCCC Strong Buy
- Analyst Count
- REFI 3
- CCCC 3
- Target Price
- REFI $20.00
- CCCC $8.67
- AVG Volume (30 Days)
- REFI 130.8K
- CCCC 1.4M
- Earning Date
- REFI 11-06-2025
- CCCC 10-30-2025
- Dividend Yield
- REFI 15.44%
- CCCC N/A
- EPS Growth
- REFI N/A
- CCCC N/A
- EPS
- REFI 1.84
- CCCC N/A
- Revenue
- REFI $56,608,781.00
- CCCC $34,240,000.00
- Revenue This Year
- REFI $9.93
- CCCC N/A
- Revenue Next Year
- REFI $4.99
- CCCC N/A
- P/E Ratio
- REFI $7.26
- CCCC N/A
- Revenue Growth
- REFI 2.58
- CCCC 16.55
- 52 Week Low
- REFI $12.76
- CCCC $1.09
- 52 Week High
- REFI $16.29
- CCCC $7.14
- Technical
- Relative Strength Index (RSI)
- REFI 39.83
- CCCC 77.23
- Support Level
- REFI $13.08
- CCCC $2.58
- Resistance Level
- REFI $14.57
- CCCC $2.75
- Average True Range (ATR)
- REFI 0.32
- CCCC 0.21
- MACD
- REFI -0.12
- CCCC 0.04
- Stochastic Oscillator
- REFI 19.46
- CCCC 94.66
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.